Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing April 06,…
February 28, 2026 09:45 ET | Source: Cogent Biosciences, Inc. Bezuclastinib mean TSS reduction deepens to –32.0 points at 48…
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another…